17,261 trials
Bronchiolitis Obliterans · Chronic Graft Versus Host Disease · Leukotriene
Primary: Number of Participants With Stable or Improved Predicted Forced Expiratory Volume 1 (FEV-1) With Published Literature — 5; 7; 6; 1 Participants
Cardiovascular Disease
Primary: Total Serum Cholesterol Levels for Alpha-cyclodextrin (a-CD) and Placebo Groups After 12-14 Weeks, Compared to Baseline — 180; 180 mg/dL — p=0.82
Atrial Fibrillation · AFib
Primary: Number of Serious Adverse Events Within 30 Days Post-Index Procedure — 0 participants
Rosacea
Primary: Total Number of Flushes for Each 2-week Period — 15.3; 16.3 Flushes count — p=0.7420
Non-alcoholic Fatty Liver Disease
Primary: Percentage Change in Liver Fat Relative to Baseline Assessed by MRI-PDFF — 13.9; 8.4 percentage change in liver fat — p=0.585
Choroidal Melanoma
Primary: To Evaluate the Safety/Efficacy of Intravitreal Injection of High Dose Ranibizumab Combined With TTT + ICG-based Photodynamic Therapy in the Treatment of Choroidal…
Pancreatic Cancer
Primary: Percentage of Patients With Overall Survival at 6 Months — 26 % of participants
Primary Biliary Cirrhosis
Primary: Absolute Change From Baseline In High-density Lipoprotein (HDL) Cholesterol Concentration — -0.38 mmol/L
Spatial Neglect · Dysphagia
Primary: P50 Percent Habituation Score — -44.12; -45.84; 113.63; 61.41 percentage of change in amplitude
Acne Vulgaris
Primary: Change From Baseline in Papule Acne Lesions at Week 10 — -4.63; -0.13 papule acne lesions — p=0.01
Chronic Iron Overload Due to Transfusion-dependant Anemias
Primary: Overall Safety as Measured by Frequency of Adverse Events — 89.5; 89.7; 15.1; 18.4 Percentage of participants
Kidney Disease · Albuminuria
Primary: The Primary Outcome Measure is Level of Albuminuria. — 927.9; 897.1 ratio
Type 1 Diabetes · Preservation of Insulin Secretion · Newly Diagnosed Type 1 Diabetes
Primary: C-peptide Response to Mixed Meal Glucose Tolerance Test (MMTT) at One Year for Subjects Given Canakinumab Compared to Placebo — 0.40; 0.41 nmol/L — p=0.86
Bipolar Disorder · Cocaine Dependence
Primary: Change From Baseline in Percentage of Cocaine-abstinent Days — 16.4; 14.5 percentage of days cocaine abstinent
Melanoma
Primary: Best Objective Response Rate (BORR) — 24 percentage of patients